Thanks for the response. As patients finish, can they look at and analyze the data? Or do they need to wait until the trial is completely finished to take a peak?
We’ve speculated about the answer but the facts would be more helpful.
If they can look at the data, will they be unblinded as well?
It’d be pretty crappy if patients that benefited didn’t get the drug. I don’t think that’s Missling’s MO. If it was, I would lose some respect for him.
Market Data 
Markets 
AI
